Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Koninklijke Philips NV — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.41, while Koninklijke Philips NV trades at $27.21 (market cap $26.29B). The key difference: Koninklijke Philips NV pays a 3.75% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| FEPI | PHG | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $32.91 |
52-Week Low | $38.13 | $24.38 |
Market Cap | — | $26.29B |
Enterprise Value | — | $32.56B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.76, down 1.6% today, with a bearish technical signal from moving averages. The ETF generates high income through weekly covered call distributions, recently transitioning to weekly payouts. Recent dividends show consistent payments around $0.20-$0.22 per share, with one larger $0.90 distribution in April 2026. The concentrated portfolio of AI and mega-cap tech names provides QQQ-like exposure but with capped upside from call writing.
The outlook remains cautious due to NAV erosion risks from the covered call strategy limiting participation in rallies. While the 25% yield attracts income seekers, total returns have lagged broader tech indices. Key risks include high portfolio concentration and market volatility impacting premium income generation. Analyst views are mixed, balancing high yield against structural limitations.
PHG trades at $27.16, up 4.22% today. The stock shows mixed signals with a bearish technical outlook but improving fundamentals, including a return to profitability in 2025 with net income of $895 million. Recent news highlights AI integration in healthcare products and new FDA clearances, supporting growth initiatives. Analyst consensus is divided with 41% buy ratings amid neutral sentiment.
The outlook is cautiously optimistic given earnings recovery and strategic partnerships, but risks include high debt levels and competitive pressures. The stock presents a value opportunity if operational improvements continue, though technical weakness suggests near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
